Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Biohit Q3'26: Strategic projects are progressing moderately as expected

Analyst Comment 2026-10-15 08:15 by Antti Siltanen
Biohit

Aiforia's partner Proscia acquired by Agilent

Analyst Comment 2026-10-14 08:39 by Antti Siltanen
Aiforia Technologies

Faron's R&D Day brought depth to trial program

Analyst Comment 2026-10-09 08:29 by Antti Siltanen
Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Bioretec seeks savings and efficiencies through new change negotiations

Analyst Comment 2026-10-09 07:07 by Antti Siltanen
Bioretec

Aiforia enters into an agreement with PathAI

Analyst Comment 2026-10-09 07:05 by Antti Siltanen
Aiforia Technologies

Nightingale: Growth boost from proteomics

Research 2026-10-08 09:01 by Antti Siltanen, Antti Luiro
Nightingale Health

Orions första biologiska läkemedelskandidat mot cancer avancerar till den kliniska fasen

Analyst Comment 2026-10-06 06:45 by Antti Siltanen
Orion

Nightingale's tests integrated into Siun sote's health checks

Analyst Comment 2026-10-06 08:11 by Antti Siltanen
Nightingale Health

Agreement between Nightingale and Archipelago Health

Analyst Comment 2026-09-24 07:31 by Antti Siltanen
Nightingale Health

Nightingale's tests to become part of Coronaria's weight management service

Analyst Comment 2026-09-22 08:15 by Antti Siltanen
Nightingale Health